Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H29NO4.ClH |
Molecular Weight | 431.952 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC1=CC=C(CC2=NC=CC3=C2C=C(OCC)C(OCC)=C3)C=C1OCC
InChI
InChIKey=UPUDVKWQBVIKBG-UHFFFAOYSA-N
InChI=1S/C24H29NO4.ClH/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20;/h9-12,14-16H,5-8,13H2,1-4H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H29NO4 |
Molecular Weight | 395.4914 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
In the US, Ethaverine is a member of the drug class peripheral vasodilators. It’s an alkaloid prepared synthetically from opium with no narcotic properties. Directly relaxes all smooth muscles, especially when they have been spasmodically contracted. Action is especially pronounced when spasm is present on coronary, cerebral, pulmonary, and peripheral arteries. Acts directly on myocardium like quinidine; depresses conduction and irritability, and prolongs refractory period. Primarily for peripheral and cerebral vascular insufficiency associated with arterial spasm; also a smooth muscle spasmolytic in spastic conditions of the GI and GU tracts. Adverse Effects ( 1%) CNS: Vertigo, headache, drowsiness. CV: Hypotension, arrhythmias. GI: Nausea, anorexia, abdominal distress, dry throat. Other: Malaise, flushing, sweating, lassitude, respiratory depression. Ethaverine may decrease levodopa effectiveness; morphine may antagonize smooth muscle relaxation effect of ethaverine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1658607 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Tumor- and drug-induced cutaneous neuro-phospholipidosis. | 1975 |
|
Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei. | 2001 Apr 13 |
|
Inhibitory effects of ethaverine, a homologue of papaverine, on dopamine content in PC12 cells. | 2001 Jan |
|
Stereoselective total synthesis of bioactive styryllactones (+)-goniofufurone, (+)7-epi-goniofufurone, (+)-goniopypyrone, (+)-goniotriol, (+)-altholactone, and (-)-etharvensin. | 2008 Jan 4 |
|
A novel flow cytometric high throughput assay for a systematic study on molecular mechanisms underlying T cell receptor-mediated integrin activation. | 2009 Jun 25 |
Patents
Sample Use Guides
for adult: 100 mg t.i.d., may increase up to 200 mg t.i.d.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1658607
0.3-30 microM ethaverine on either side of the dihydropyridine-sensitive, L-type calcium channel from porcine cardiac muscle caused a reduction in the channel open probability (EC50 approximately 1 microM), with the higher concentrations inhibiting channel activity almost completely
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:50 GMT 2023
by
admin
on
Fri Dec 15 14:59:50 GMT 2023
|
Record UNII |
6Z6T599E49
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6Z6T599E49
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
DTXSID2047779
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
213-573-9
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
m5053
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB01996MIG
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL1555736
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
C72769
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
525044
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
13796
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
985-13-7
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
100000087299
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | |||
|
235229
Created by
admin on Fri Dec 15 14:59:51 GMT 2023 , Edited by admin on Fri Dec 15 14:59:51 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |